These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 28131193)

  • 1. The heterozygous R1441C mutation of leucine-rich repeat kinase 2 gene in a Chinese patient with Parkinson disease: A five-year follow-up and literatures review.
    Peng F; Sun YM; Chen C; Luo SS; Li DK; Wang YX; Yang K; Liu FT; Zuo CT; Ding ZT; An Y; Wu JJ; Wang J
    J Neurol Sci; 2017 Feb; 373():23-26. PubMed ID: 28131193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic screening for the LRRK2 R1441C and G2019S mutations in Parkinsonian patients from Campania.
    De Rosa A; De Michele G; Guacci A; Carbone R; Lieto M; Peluso S; Picillo M; Barone P; Salemi F; Laiso A; Saccà F; Tessitore A; Pellecchia MT; Bonifati V; Criscuolo C
    J Parkinsons Dis; 2014; 4(1):123-8. PubMed ID: 24496098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical characterization of patients with leucine-rich repeat kinase 2 genetic variants in Japan.
    Li Y; Ikeda A; Yoshino H; Oyama G; Kitani M; Daida K; Hayashida A; Ogaki K; Yoshida K; Kimura T; Nakayama Y; Ito H; Sugeno N; Aoki M; Miyajima H; Kimura K; Ueda N; Watanabe M; Urabe T; Takanashi M; Funayama M; Nishioka K; Hattori N
    J Hum Genet; 2020 Sep; 65(9):771-781. PubMed ID: 32398759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating the Role of SNCA, LRRK2, and GBA in Chinese Patients With Early-Onset Parkinson's Disease.
    Chen Y; Gu X; Ou R; Zhang L; Hou Y; Liu K; Cao B; Wei Q; Li C; Song W; Zhao B; Wu Y; Cheng J; Shang H
    Mov Disord; 2020 Nov; 35(11):2046-2055. PubMed ID: 32677286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic analysis for five LRRK2 mutations in a Sardinian parkinsonian population: importance of G2019S and R1441C mutations in sporadic Parkinson's disease patients.
    Floris G; Cannas A; Solla P; Murru MR; Tranquilli S; Corongiu D; Rolesu M; Cuccu S; Sardu C; Marrosu F; Marrosu MG
    Parkinsonism Relat Disord; 2009 May; 15(4):277-80. PubMed ID: 18805725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation of fourteen isogenic cell lines for Parkinson's disease-associated leucine-rich repeat kinase (LRRK2).
    Beylina A; Langston RG; Rosen D; Reed X; Cookson MR
    Stem Cell Res; 2021 May; 53():102354. PubMed ID: 34087985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prodromal phase of leucine-rich repeat kinase 2-associated Parkinson disease: Clinical and imaging Studies.
    Pont-Sunyer C; Tolosa E; Caspell-Garcia C; Coffey C; Alcalay RN; Chan P; Duda JE; Facheris M; Fernández-Santiago R; Marek K; Lomeña F; Marras C; Mondragon E; Saunders-Pullman R; Waro B;
    Mov Disord; 2017 May; 32(5):726-738. PubMed ID: 28370517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical features of LRRK2 parkinsonism.
    Haugarvoll K; Wszolek ZK
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 3():S205-8. PubMed ID: 20082991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Phenotype of LRRK2 R1441C in 2 Chinese Sisters.
    Lim SY; Lim JL; Ahmad-Annuar A; Lohmann K; Tan AH; Lim KB; Tay YW; Shing YL; Muthusamy KA; Bauer P; Rolfs A; Klein C
    Neurodegener Dis; 2020; 20(1):39-45. PubMed ID: 32580205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic analysis of LRRK2 mutations in patients with Parkinson disease.
    Deng H; Le W; Guo Y; Hunter CB; Xie W; Huang M; Jankovic J
    J Neurol Sci; 2006 Dec; 251(1-2):102-6. PubMed ID: 17097110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional Study.
    Simuni T; Brumm MC; Uribe L; Caspell-Garcia C; Coffey CS; Siderowf A; Alcalay RN; Trojanowski JQ; Shaw LM; Seibyl J; Singleton A; Toga AW; Galasko D; Foroud T; Nudelman K; Tosun-Turgut D; Poston K; Weintraub D; Mollenhauer B; Tanner CM; Kieburtz K; Chahine LM; Reimer A; Hutten S; Bressman S; Marek K;
    Mov Disord; 2020 May; 35(5):833-844. PubMed ID: 32073681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LRRK2 mutations in Spanish patients with Parkinson disease: frequency, clinical features, and incomplete penetrance.
    Gaig C; Ezquerra M; Marti MJ; Muñoz E; Valldeoriola F; Tolosa E
    Arch Neurol; 2006 Mar; 63(3):377-82. PubMed ID: 16533964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequency of LRRK2 mutations in early- and late-onset Parkinson disease.
    Clark LN; Wang Y; Karlins E; Saito L; Mejia-Santana H; Harris J; Louis ED; Cote LJ; Andrews H; Fahn S; Waters C; Ford B; Frucht S; Ottman R; Marder K
    Neurology; 2006 Nov; 67(10):1786-91. PubMed ID: 17050822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The heterozygous A53T mutation in the alpha-synuclein gene in a Chinese Han patient with Parkinson disease: case report and literature review.
    Xiong WX; Sun YM; Guan RY; Luo SS; Chen C; An Y; Wang J; Wu JJ
    J Neurol; 2016 Oct; 263(10):1984-92. PubMed ID: 27393118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical features of LRRK2-associated Parkinson's disease].
    Pchelina SN; Ivanova ON; Emel'ianov AK; Iakimovskiĭ AF
    Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(12):56-62. PubMed ID: 22433811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Motor phenotype of LRRK2 G2019S carriers in early-onset Parkinson disease.
    Alcalay RN; Mejia-Santana H; Tang MX; Rosado L; Verbitsky M; Kisselev S; Ross BM; Louis ED; Comella CL; Colcher A; Jennings D; Nance MA; Bressman S; Scott WK; Tanner C; Mickel SF; Andrews HF; Waters CH; Fahn S; Cote LJ; Frucht SJ; Ford B; Rezak M; Novak K; Friedman JH; Pfeiffer R; Marsh L; Hiner B; Siderowf A; Caccappolo E; Ottman R; Clark LN; Marder KS
    Arch Neurol; 2009 Dec; 66(12):1517-22. PubMed ID: 20008657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of ten LRRK2 variants in Parkinson's disease: A comprehensive review.
    Simpson C; Vinikoor-Imler L; Nassan FL; Shirvan J; Lally C; Dam T; Maserejian N
    Parkinsonism Relat Disord; 2022 May; 98():103-113. PubMed ID: 35654702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LRRK2 BAC transgenic rats develop progressive, L-DOPA-responsive motor impairment, and deficits in dopamine circuit function.
    Sloan M; Alegre-Abarrategui J; Potgieter D; Kaufmann AK; Exley R; Deltheil T; Threlfell S; Connor-Robson N; Brimblecombe K; Wallings R; Cioroch M; Bannerman DM; Bolam JP; Magill PJ; Cragg SJ; Dodson PD; Wade-Martins R
    Hum Mol Genet; 2016 Mar; 25(5):951-63. PubMed ID: 26744332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutations in LRRK2 other than G2019S are rare in a north American-based sample of familial Parkinson's disease.
    Pankratz N; Pauciulo MW; Elsaesser VE; Marek DK; Halter CA; Rudolph A; Shults CW; Foroud T; Nichols WC;
    Mov Disord; 2006 Dec; 21(12):2257-60. PubMed ID: 17078063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High prevalence of LRRK2 mutations in familial and sporadic Parkinson's disease in Portugal.
    Ferreira JJ; Guedes LC; Rosa MM; Coelho M; van Doeselaar M; Schweiger D; Di Fonzo A; Oostra BA; Sampaio C; Bonifati V
    Mov Disord; 2007 Jun; 22(8):1194-201. PubMed ID: 17469194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.